title: Novel anti-viral therapy: drugs that block HIV entry at different target sites.
abstract: Drugs that block the entry of human immunodeficiency virus type 1 (HIV-1) into host cells abrogate the establishment of a productive infection and should ideally diminish the chances of HIV-1 developing resistance. This review will give an overview of the mechanism by which the envelope glycoprotein mediates HIV-1 entry and will summarize current drug developments.
authors.affiliation: Department of Virology, Paul-Ehrlich-Institut, Paul-Ehrlich Strasse 51-59, 63225 Langen, Germany.
authors.forename: Sandra
authors.initials: S
authors.lastname: Siegert
authors.forename: Peter
authors.initials: P
authors.lastname: Schnierle
authors.forename: Barbara S
authors.initials: BS
authors.lastname: Schnierle
mesh_terms: D000595:Amino Acid Sequence; D065100:CCR5 Receptor Antagonists; D002478:Cells, Cultured; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D006801:Humans; D008969:Molecular Sequence Data; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors
chemical_list: D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors; D019718:Receptors, CXCR4